AgingResearch.NewsJoin free

Phase 3Active, not recruitingAge-related condition

A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)

A Multicenter, Double-Blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Long-Term Protective Efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above

Sponsor
MAXVAX Biotechnology Limited Liability Company (Industry)
Enrolment
12,000 planned
Conditions
Herpes Zoster
Interventions
Recombinant Zoster Vaccine (CHO Cell); NaCl solution Placebo
Ages
adults, older adults
Registry
NCT07293065

Full record on ClinicalTrials.gov

From the registry

The purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete immunization with the 0- and 2-month immunization schedule in individuals aged 40 years and older.

Primary outcomes

  • The person-year incidence of confirmed herpes zoster cases among individuals aged 40 years and older, 13 to 36 months after completing the full vaccination course with the investigational vaccine according to the 0- and 2-month immunization schedule.

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Registered

  5. Started